CareRx Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

CareRx şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

0.5%

Geri Alım Getirisi

Toplam Hissedar Getirisi	0.5%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

Oct 03

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Aug 11

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Apr 22

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

Mar 17

Is CareRx Corporation's (TSE:CRRX) Shareholder Ownership Skewed Towards Insiders?

Mar 15

Trade Alert: The Chairman Emeritus Of CareRx Corporation (TSE:CRRX), Jack Shevel, Has Just Spent CA$850k Buying 9.4% More Shares

Feb 08

Reflecting on CareRx's (TSE:CRRX) Share Price Returns Over The Last Three Years

Dec 29

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: CRRX şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: CRRX şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

CareRx Piyasaya Karşı Temettü Getirisi

CRRX temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CRRX)	n/a
Pazarın Alt %25'i (CA)	1.7%
Pazarın En İyi %25'i (CA)	6.1%
Sektör Ortalaması (Consumer Retailing)	1.2%
Analist tahmini (CRRX) (3 yıla kadar)	n/a

Önemli Temettü: CRRX şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, CRRX şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: CRRX şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: CRRX herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

CareRx Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q3, 2024 Results on Nov 08, 2024

CareRx (TSE:CRRX) Seems To Use Debt Quite Sensibly

CareRx Corporation Appoints Suzanne Brand as Chief Financial Officer, Effective October 1, 2024

Analyst Estimates: Here's What Brokers Think Of CareRx Corporation (TSE:CRRX) After Its Second-Quarter Report

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

CareRx Corporation to Report Q2, 2024 Results on Aug 08, 2024

New minor risk - Insider selling

CareRx Corporation Announces Board Changes

Consensus EPS estimates increase by 386%

CareRx Corporation Announces CFO Transition

First quarter 2024 earnings: EPS exceeds analyst expectations

Does CareRx (TSE:CRRX) Have A Healthy Balance Sheet?

Market Participants Recognise CareRx Corporation's (TSE:CRRX) Revenues Pushing Shares 28% Higher

CareRx Corporation, Annual General Meeting, May 28, 2024

CareRx Corporation Reports Goodwill and Intangible Assets Impairment Charges for the Fourth Quarter Ended December 31, 2023

Full year 2023 earnings: EPS misses analyst expectations

CareRx Corporation to Report Q4, 2023 Results on Mar 07, 2024

New major risk - Revenue and earnings growth

Third quarter 2023 earnings: EPS exceeds analyst expectations

CareRx Corporation to Report Q3, 2023 Results on Nov 08, 2023

CareRx (TSE:CRRX) Takes On Some Risk With Its Use Of Debt

What You Can Learn From CareRx Corporation's (TSE:CRRX) P/S

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q2, 2023 Results on Aug 10, 2023

Less than half of directors are independent

Carerx Corporation Announces Director Changes

First quarter 2023 earnings released: CA$0.039 loss per share (vs CA$0.059 loss in 1Q 2022)

Consensus EPS estimates fall by 29%

Forecast breakeven date pushed back to 2025

Price target decreased by 11% to CA$5.23

Full year 2022 earnings released: CA$0.72 loss per share (vs CA$0.65 loss in FY 2021)

CareRx Corporation has completed a Follow-on Equity Offering in the amount of CAD 8.0001 million.

CareRx Corporation announced that it expects to receive CAD 8.0001 million in funding

CareRx Announces Retirement of Dr. Jack Shevel as Director Effective December 31, 2022

No longer forecast to breakeven

Price target decreased to CA$6.09

Less than half of directors are independent

Price target decreased to CA$6.15

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

CareRx Corporation to Report Q3, 2022 Results on Nov 09, 2022

CareRx (TSE:CRRX) Has A Somewhat Strained Balance Sheet

Consensus forecasts updated

Price target decreased to CA$6.93

Carerx Corporation Reports Goodwill and Intangible Assets Impairment Changes for the Three Months Ended June 30, 2022

CareRx Corporation to Report Q2, 2022 Results on Aug 15, 2022

President recently sold CA$230k worth of stock

CareRx Corporation (TSX:CRRX) completed the acquisition of Hogan Pharmacy Partners Ltd.

Consensus EPS estimates fall by 597%

Price target decreased to CA$8.52

These 4 Measures Indicate That CareRx (TSE:CRRX) Is Using Debt Extensively

Forecast breakeven date pushed back to 2024

CareRx Corporation to Report Q1, 2022 Results on May 11, 2022

Consensus forecasts updated

Less than half of directors are independent

CareRx Corporation Announces Executive Changes

CareRx Corporation, Annual General Meeting, Jun 07, 2022

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

CareRx Corporation (TSX:CRRX) entered into a definitive asset purchase agreement to acquire Hogan Pharmacy Partners Ltd for $4.4 million.

Consensus forecasts updated

No longer forecast to breakeven

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Carerx Corporation Expands the Scope and Product Offering of Its Medical Supplies Business Under A New Brand, Revicare

Here's Why CareRx (TSE:CRRX) Has A Meaningful Debt Burden

Third quarter 2021 earnings released: CA$0.11 loss per share (vs CA$0.28 loss in 3Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of Long-Term Care Pharmacy Division of Medical Pharmacies Group Limited for CAD 72.9 million.

Consensus EPS estimates fall to -CA$0.72

Second quarter 2021 earnings released: CA$0.28 loss per share (vs CA$0.75 loss in 2Q 2020)

CareRx Corporation (TSX:CRRX) completed the acquisition of pharmacy fulfillment centre and portion of long-term care pharmacy services business of Rexall Pharma Plus Ltd.

Director Lyle Oberg has left the company

Director Peter Brown has left the company

Consensus forecasts updated

Price target increased to CA$8.33

First quarter 2021 earnings released: CA$0.21 loss per share (vs CA$0.37 profit in 1Q 2020)